Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 13

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 13
---
 defined in Rule 415 of the Securities Act, including without limitation                 
 sales made directly on Nasdaq, on any other existing trading market for the common stock in the United States. Dawson James is not         
 required to sell any certain number of shares or dollar amount of our Common Stock, but will act as a sales agent and use commercially     
 reasonable efforts to sell on our behalf all of the shares of Common Stock requested to be sold by us, consistent with its normal          
 trading and sales practices, subject to the terms of the sales agreement. See section titled “Plan of Distribution”                        
 on page S-14 of this prospectus supplement.                                                                                                |
| Use                                        
 of Proceeds                                |     | We                                                                                                                                         
 currently intend to use the net proceeds from these sales for general corporate purposes, including working capital, operating expenses,   
 and capital expenditures. See “Use of Proceeds” on page S-10 of this prospectus supplement.                                                |
| Risk                                       
 Factors                                    |     | An                                                                                                                                         
 investment in our securities is highly speculative and subject to substantial risks. You should consider the “Risk                         
 Factors” and the “Cautionary Note Regarding Forward-Looking Statements” included and incorporated by                                       
 reference in this prospectus supplement and the accompanying prospectus, including the risk factors incorporated by reference from         
 our filings with the SEC.                                                                                                                  |
| Nasdaq                                     
 Capital Market symbol                      |     | Our                                                                                                                                        
 Common Stock is listed on the Nasdaq Capital Market under the symbol “LNAI.”                                                               |

The number of shares of our Common Stock
to be outstanding immediately after this offering
is based on 23,430,653 shares of Common Stock
as of December 1, 2025, which excludes:

| ● | 267,695 shares of Common Stock issuable in connection with the acquisition of Renovaro Cube as contingent consideration;        |
| ● | 626,983 shares of Common Stock issuable upon the exercise of warrants at a weighted average exercise prices of $9.09 per share; |
| ● | 242,482 shares of Common Stock issuable upon the exercise of options at a weighted average exercise price of $7.37 per share.   |

Unless otherwise indicated,
all information in this prospectus reflects the
Reverse Stock Split and assumes no issuance of the outstanding contingent consideration described
above.

<div align='center'>S-7

RISK FAC TORS</div>

Investing in our securities is highly spe culative and involves a high deg ree